Fortis Healthcare Limited

Key Appointment Details

  • Agilus Diagnostics Limited, a subsidiary of Fortis Healthcare Limited, appointed Mr. Vijender Singh as Managing Director & Chief Executive Officer effective July 20, 2026.
  • The appointment occurred at 11:00 AM on July 20, 2026.
  • Mr. Singh replaces Dr. Anand K, who resigned after nearly six years with the company to pursue opportunities outside the organization.
  • The Board and management thanked Dr. Anand K for his contributions.

Executive Background

Mr. Vijender Singh brings over three decades of leadership experience across diagnostics, healthcare, consumer healthcare and FMCG sectors. His previous roles include:

  • Chairman and Managing Director of Diagnum Healthcare (focusing on strategic growth, governance and business development)
  • Group CEO of Metropolis Healthcare
  • CEO of Healthians
  • Nearly a decade with Dr. Lal PathLabs, where he played a key role in building one of India's most successful diagnostics platforms
  • Operating Partner with Jashvik Capital
  • Leadership roles with Ranbaxy Consumer Healthcare, Bausch & Lomb and Blow Plast

At Dr. Lal PathLabs, he played a key role in building the company's retail-focused diagnostics model and contributed to its successful IPO journey. As Group CEO of Metropolis Healthcare, he led the integration and transformation of multiple acquired businesses and played a significant role in the company's successful public listing.

Management Commentary

Dr. Ashutosh Raghuvanshi, Managing Director & Chief Executive Officer of Fortis Healthcare Limited and Chairman of Agilus Diagnostics, stated: "We are delighted to welcome Vijender Singh as the Managing Director & Chief Executive Officer of Agilus Diagnostics. Vijender brings extensive experience in building and scaling diagnostic businesses, driving operational excellence and creating sustainable value across healthcare organisations. His deep understanding of the diagnostics industry, coupled with a strong track record of business transformation and customer-centric growth, makes him exceptionally well positioned to lead Agilus into its next phase of growth."

Mr. Vijender Singh commented: "I am excited to join Agilus Diagnostics at a time when the diagnostics industry is witnessing significant transformation and growth. Agilus has built a strong reputation for quality, scientific excellence and customer trust, supported by a vast network and talented team. I look forward to working closely with the leadership team and employees to further strengthen the organisation's market position, expand access to high-quality diagnostics, enhance operational excellence and create long-term value for patients, customers and all stakeholders."

Financial Impact

Financial impact not quantified in the disclosure.